Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
Clinical trial NCT02759588 · COMPLETED
Trial details
- NCT number
- NCT02759588
- Sponsor
- Genelux Corporation
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-05-01
- Primary completion
- 2021-12-31
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.